Lantheus (LNTH) Upgraded by ValuEngine to Buy

Lantheus (NASDAQ:LNTH) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Saturday.

LNTH has been the subject of several other reports. Jefferies Group upped their target price on Lantheus from $22.00 to $27.00 and gave the stock a “buy” rating in a research note on Friday, November 3rd. Wells Fargo & Co upgraded Lantheus from a “market perform” rating to an “outperform” rating in a research note on Thursday, November 2nd. Zacks Investment Research upgraded Lantheus from a “hold” rating to a “strong-buy” rating and set a $26.00 target price for the company in a research note on Tuesday, November 7th. BidaskClub upgraded Lantheus from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. Finally, Credit Suisse Group upped their price target on shares of Lantheus from $19.00 to $23.00 and gave the stock a “neutral” rating in a report on Friday, November 3rd. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $24.75.

Lantheus (NASDAQ:LNTH) traded down $1.25 during midday trading on Friday, reaching $21.90. The company’s stock had a trading volume of 391,952 shares, compared to its average volume of 284,685. The company has a quick ratio of 2.46, a current ratio of 2.96 and a debt-to-equity ratio of -3.41. Lantheus has a 12-month low of $8.25 and a 12-month high of $24.45. The company has a market capitalization of $868.26, a PE ratio of 27.04, a PEG ratio of 1.50 and a beta of 0.95.

In other news, insider Michael P. Duffy sold 11,917 shares of the company’s stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $21.63, for a total transaction of $257,764.71. Following the completion of the transaction, the insider now directly owns 152,301 shares in the company, valued at $3,294,270.63. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO John W. Crowley sold 3,866 shares of the company’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $23.52, for a total transaction of $90,928.32. The disclosure for this sale can be found here. Insiders have sold 48,752 shares of company stock valued at $1,077,129 over the last quarter. Company insiders own 2.30% of the company’s stock.

Several large investors have recently made changes to their positions in LNTH. Quantbot Technologies LP acquired a new position in shares of Lantheus during the second quarter worth $117,000. Sei Investments Co. increased its holdings in shares of Lantheus by 189.6% during the third quarter. Sei Investments Co. now owns 7,829 shares of the medical equipment provider’s stock worth $139,000 after buying an additional 5,126 shares in the last quarter. Bank of Montreal Can increased its holdings in Lantheus by 371.6% in the fourth quarter. Bank of Montreal Can now owns 6,819 shares of the medical equipment provider’s stock valued at $139,000 after purchasing an additional 5,373 shares during the period. Teachers Retirement System of The State of Kentucky acquired a new stake in Lantheus in the second quarter valued at $141,000. Finally, LS Investment Advisors LLC increased its holdings in Lantheus by 47.1% in the third quarter. LS Investment Advisors LLC now owns 9,306 shares of the medical equipment provider’s stock valued at $166,000 after purchasing an additional 2,981 shares during the period. Institutional investors own 91.22% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Lantheus (LNTH) Upgraded by ValuEngine to Buy” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/03/lantheus-lnth-upgraded-by-valuengine-to-buy.html.

About Lantheus

Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply